Treatment with luteinizing hormone-releasing hormone antagonist SE-75 decreases levels of epidermal growth factor receptor and its mRNA in OV-1063 human epithelial ovarian cancer xenografts in nude mice

W. Shirahige, C. B. Cook, J. Pinski, G. Halmos, R. Nair, A. V. Schally

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

The aim of this study was to investigate the effect of administration of LH-RH antagonist SB-75 and agonist (D-Trp6]LH-RH on receptors for epidermal growth factor (EGF) in OV-1063 human epithelial ovarian cancer. Female athymic nude mice bearing xenografts of OV-1063 human epithelial ovarian cancer were treated for 3 weeks with the modern LH-releasing hormone (LH-RH) antagonist [Ac-D-Nal(2)1, D-Phe(4Cl)2, D-Pal(3)3, D-Cit6; D-Ala10] LH-RH (SB-75, Cetrorelix), the agonist [D-Trp6]LH-RH, or bombesin/gastrin-releasing peptide antagonist RC-3095. SB-75 and [D-Trp6] LH-RH were injected s.c. at doses of 100 μg/day, and RC-3095 was injected at a dose of 40 μg/day. Tumor growth, as measured by percentage change in tumor volume, was significantly inhibited by the treatment with SB-75, but not by [D-Trp6] LH-RH or RC-3095. Treatment with SB-75 greatly decreased the levels of mRNA for EGF receptor and reduced the number of EGF binding sites on tumor membranes. Effects, of SB-75 on EGF receptors might be related to inhibition of tumor growth. Our findings support the view that LH-RH antagonists such as SB-75 could be considered for possible hormonal therapy of epithelial ovarian cancer.

Original languageEnglish (US)
Pages (from-to)1031-1035
Number of pages5
JournalInternational journal of oncology
Volume5
Issue number5
StatePublished - Jan 1 1994
Externally publishedYes

Keywords

  • Epidermal growth factor receptor
  • LH-RH analogs
  • Northern blot analysis
  • Nude mice
  • Ovarian carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Treatment with luteinizing hormone-releasing hormone antagonist SE-75 decreases levels of epidermal growth factor receptor and its mRNA in OV-1063 human epithelial ovarian cancer xenografts in nude mice'. Together they form a unique fingerprint.

  • Cite this